Executive Debrief

The Debrief offers concise updates on China's evolving access landscape for innovative medicines to senior-level decision-makers and global teams. It distills trends, strives for a balanced perspective on opportunities and challenges, and helps global teams connect the dots as they develop China-tailored strategies and plans.

May

NRDL+ Policy Watch Debrief: Raising the Bar for Innovation

The April debrief analyzed recent advancements to the NHSA's lifecycle pricing framework and key policy directions for Huiminbao, focusing on their combined effects on the pricing and access pathways for innovative medicines in China.

May 15, 2024

Apr

NRDL+ 2024 Annual Executive Debrief: The State of Access for Innovative Medicines in China

In this inaugural annual NRDL+ debrief, we comprehensively examined pivotal developments and trends across basic medical insurance schemes, the commercial

Apr 11, 2024

1 min read